Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Aug 22;2014(8):CD009096.
doi: 10.1002/14651858.CD009096.pub2.

Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension

Edmond C K Li  1 , Balraj S Heran, James M Wright
Affiliations
Meta-Analysis

Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension

Edmond C K Li et al. Cochrane Database Syst Rev. .

Abstract

Background: Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg). However, while ACE inhibitors have been shown to reduce mortality and morbidity in placebo-controlled trials, ARBs have not. Therefore, a comparison of the efficacies of these two drug classes in primary hypertension for preventing total mortality and cardiovascular events is important.

Objectives: To compare the effects of ACE inhibitors and ARBs on total mortality and cardiovascular events, and their rates of withdrawals due to adverse effects (WDAEs), in people with primary hypertension.

Search methods: We searched the Cochrane Hypertension Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the World Health Organization (WHO) International Clinical Trials Registry Platform, and the ISI Web of Science up to July 2014. We contacted study authors for missing and unpublished information, and also searched the reference lists of relevant reviews for eligible studies.

Selection criteria: We included randomized controlled trials enrolling people with uncontrolled or controlled primary hypertension with or without other risk factors. Included trials must have compared an ACE inhibitor and an ARB in a head-to-head manner, and lasted for a duration of at least one year. If background blood pressure lowering agents were continued or added during the study, the protocol to do so must have been the same in both study arms.

Data collection and analysis: We used standard methodological procedures expected by The Cochrane Collaboration.

Main results: Nine studies with 11,007 participants were included. Of the included studies, five reported data on total mortality, three reported data on total cardiovascular events, and four reported data on cardiovascular mortality. No study separately reported cardiovascular morbidity. In contrast, eight studies contributed data on WDAE. Included studies were of good to moderate quality. There was no evidence of a difference between ACE inhibitors and ARBs for total mortality (risk ratio (RR) 0.98; 95% confidence interval (CI) 0.88 to 1.10), total cardiovascular events (RR 1.07; 95% CI 0.96 to 1.19), or cardiovascular mortality (RR 0.98; 95% CI 0.85 to 1.13). Conversely, a high level of evidence indicated a slightly lower incidence of WDAE for ARBs as compared with ACE inhibitors (RR 0.83; 95% CI 0.74 to 0.93; absolute risk reduction (ARR) 1.8%, number needed to treat for an additional beneficial outcome (NNTB) 55 over 4.1 years), mainly attributable to a higher incidence of dry cough with ACE inhibitors. The quality of the evidence for mortality and cardiovascular outcomes was limited by possible publication bias, in that several studies were initially eligible for inclusion in this review, but had no extractable data available for the hypertension subgroup. To this end, the evidence for total mortality was judged to be moderate, while the evidence for total cardiovascular events was judged to be low by the GRADE approach.

Authors' conclusions: Our analyses found no evidence of a difference in total mortality or cardiovascular outcomes for ARBs as compared with ACE inhibitors, while ARBs caused slightly fewer WDAEs than ACE inhibitors. Although ACE inhibitors have shown efficacy in these outcomes over placebo, our results cannot be used to extrapolate the same conclusion for ARBs directly, which have not been studied in placebo-controlled trials for hypertension. Thus, the substitution of an ARB for an ACE inhibitor, while supported by evidence on grounds of tolerability, must be made in consideration of the weaker evidence for the efficacy of ARBs regarding mortality and morbidity outcomes compared with ACE inhibitors. Additionally, our data mostly derives from participants with existing clinical sequelae of hypertension, and it would be useful to have data from asymptomatic people to increase the generalizability of this review. Unpublished subgroup data of hypertensive participants in existing trials comparing ACE inhibitors and ARBs needs to be made available for this purpose.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

1
1
Identification and assessment of records for inclusion into the review.
2
2
Risk of bias summary: review authors' judgments about each risk of bias item for each included study.
3
3
Forest plot of comparison: 1 All angiotensin converting enzyme (ACE) inhibitors versus all angiotensin receptor blockers (ARBs), outcome: 1.1 Total mortality.
4
4
Forest plot of comparison: 1 All angiotensin converting enzyme (ACE) inhibitors versus all angiotensin receptor blockers (ARBs), outcome: 1.2 Total cardiovascular events.
5
5
Forest plot of comparison: 1 All angiotensin converting enzyme (ACE) inhibitors versus all angiotensin receptor blockers (ARBs), outcome: 1.3 Cardiovascular mortality.
6
6
Forest plot of comparison: 1 All angiotensin converting enzyme (ACE) inhibitors versus all angiotensin receptor blockers (ARBs), outcome: 1.4 Withdrawal due to adverse effects.
1.1
1.1. Analysis
Comparison 1 All angiotensin converting enzyme (ACE) inhibitors versus all angiotensin receptor blockers (ARBs), Outcome 1 Total mortality.
1.2
1.2. Analysis
Comparison 1 All angiotensin converting enzyme (ACE) inhibitors versus all angiotensin receptor blockers (ARBs), Outcome 2 Total cardiovascular events.
1.3
1.3. Analysis
Comparison 1 All angiotensin converting enzyme (ACE) inhibitors versus all angiotensin receptor blockers (ARBs), Outcome 3 Cardiovascular mortality.
1.4
1.4. Analysis
Comparison 1 All angiotensin converting enzyme (ACE) inhibitors versus all angiotensin receptor blockers (ARBs), Outcome 4 Withdrawal due to adverse effects.
See this image and copyright information in PMC

Comment in

References

References to studies included in this review

Bremner 1997 {published data only}
    1. Bremner AD, Baur M, Oddou‐Stock P, Bodin F. Valsartan: long‐term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clinical & Experimental Hypertension 1997;19(8):1263‐85. - PubMed
DETAIL 2004 {unpublished data only}
    1. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin‐receptor blockade versus converting‐enzyme inhibition in Type 2 diabetes and nephropathy. New England Journal of Medicine 2004;351(19):1952‐61. - PubMed
Fogari 2008 {published data only}
    1. Fogari R, Derosa G, Ferrari I, Corradi L, Zoppi A, Lazzari P, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P‐wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. American Journal of Hypertension 2008;21(9):1034‐9. - PubMed
Fogari 2011 {published data only}
    1. Fogari R, Mugellini A, Zoppi A, Preti P, Destro M, Lazzari P, et al. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics 2011;17(1):34‐43. [DOI: 10.1177/1074248410395018] - DOI - PubMed
Fogari 2012 {published data only}
    1. Fogari R, Zoppi A, Mugellini A, Maffioli P, Preti P, Derosa G. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert Opinion on Pharmacotherapy 2012;13(8):1091‐9. - PubMed
Lacourciere 2000 {published data only}
    1. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, et al. Long‐term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney International 2000;58(2):762‐9. - PubMed
ONTARGET 2008 {published data only}
    1. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high‐risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal 2004;148(1):52‐61. - PubMed
    1. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schurnacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine 2008; Vol. 358, issue 15:1547‐59. - PubMed
Sozen 2009 {published data only}
    1. Sozen AB, Kayacan MS, Tansel T, Celebi A, Kudat H, Akkaya V, et al. Drugs with blocking effects on the renin‐angiotensin‐aldosterone system do not improve endothelial dysfunction long‐term in hypertensive patients. Journal of International Medical Research 2009;37(4):996‐1002. - PubMed
Spoelstra‐de 2006 {published data only}
    1. Spoelstra‐de Man AME, Ittersum FJ, Schram MT, Kamp O, Dijk RAJM, Ijzerman RG, et al. Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension. Journal of Human Hypertension 2006;20(8):599‐611. - PubMed

References to studies excluded from this review

Akinboboye 2002 {published data only}
    1. Akinboboye OO, Chou R‐L, Bergmann SR. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. Journal of the American College of Cardiology 2002;40(4):703‐9. - PubMed
CORD 2009 {published data only}
    1. Spinar J, Vitovec J, Soucek M, Dusek L, Pavlik T, Invesigators C. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. Vnitrni Lekarstvi 2009;55(5):481‐8. - PubMed
Derosa 2011 {published data only}
    1. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, Fogari E, et al. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertension Research ‐ Clinical & Experimental 2011;34(1):145‐51. - PubMed
Didangelos 2006 {published data only}
    1. Didangelos TP, Arsos GA, Karamitsos DT, Athyros VG, Georga SD, Karatzas ND. Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. Journal of Diabetes & its Complications 2006;20(1):1‐7. - PubMed
el‐Agroudy 2003 {published data only}
    1. el‐Agroudy AE, Hassan NA, Foda MA, Ismail AM, el‐Sawy EA, Mousa O, et al. Effect of angiotensin II receptor blocker on plasma levels of TGF‐beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. American Journal of Nephrology 2003;23(5):300‐6. - PubMed
ELITE II 2000 {published data only}
    1. Pitt B, Poole‐Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial ‐ the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355(9215):1582‐7. - PubMed
Franke 1997 {published data only}
    1. Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. Journal of Human Hypertension 1997;11 Suppl 2:S61‐2. - PubMed
Guntekin 2008 {published data only}
    1. Guntekin U, Gunes Y, Tuncer M, Simsek H, Gunes A. Comparison of the effects of quinapril and irbesartan on P‐wave dispersion in hypertensive patients. Advances in Therapy 2008;25(8):775‐86. - PubMed
Hou 2007 {published data only}
    1. Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. Journal of the American Society of Nephrology 2007;18(6):1889‐98. - PubMed
Ichihara 2005 {published data only}
    1. Ichihara A, Hayashi M, Kaneshiro Y, Takemitsu T, Homma K, Kanno Y, et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. American Journal of Kidney Diseases 2005;45(5):866‐74. - PubMed
Nakamura 2010 {published data only}
    1. Nakamura T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. European Journal of Clinical Investigation 2010;40(9):790‐6. - PubMed
Nakao 2003 {published data only}
    1. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin‐II receptor blocker and angiotensin‐converting‐enzyme inhibitor in non‐diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361(9352):117‐24. - PubMed
Neutel 1999 {published data only}
    1. Neutel JM, Frishman WH, Oparil S, Papademitriou V, Guthrie G. Comparison of telmisartan with lisinopril in patients with mild‐to‐moderate hypertension. American Journal of Therapeutics 1999;6(3):161‐6. - PubMed
OPTIMAAL 2002 {published data only}
    1. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high‐risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360(9335):752‐60. - PubMed
Rizzoni 2005 {published data only}
    1. Rizzoni D, Porteri E, Ciuceis C, Sleiman I, Rodella L, Rezzani R, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with non insulin‐dependent diabetes mellitus. Hypertension 2005;45(4):659‐65. - PubMed
Schram 2005 {published data only}
    1. Schram MT, Ittersum FJ, Spoelstra‐de Man A, Dijk RAJM, Schalkwijk CG, Ijzerman RG, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double‐blind, randomized clinical trial. Journal of Human Hypertension 2005;19(6):429‐37. - PubMed
Sengul 2006 {published data only}
    1. Sengul AM, Altuntas Y, Kurklu A, Aydin L. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Research & Clinical Practice 2006;71(2):210‐9. - PubMed
Shoda 2006 {published data only}
    1. Shoda J, Kanno Y, Suzuki H. A five‐year comparison of the renal protective effects of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in patients with non‐diabetic nephropathy. Internal Medicine 2006;45(4):193‐8. - PubMed
Suzuki 2004 {published data only}
    1. Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Therapeutic Apheresis and Dialysis 2004, issue 4:320‐7. - PubMed
Tutuncu 2001 {published data only}
    1. Tutuncu NB, Gurlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetologica 2001;38(4):157‐61. - PubMed
Ulusoy 2010 {published data only}
    1. Ulusoy S, Ozkan G, Orem C, Kaynar K, Kosucu P, Kiris A. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. Renal Failure 2010;32(8):913‐7. - PubMed
VALIANT 2003 {published data only}
    1. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J‐L, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine 2003;349(20):1893‐906. - PubMed
Veronesi 2007 {published data only}
    1. Veronesi M, Cicero AFG, Prandin MG, Dormi A, Cosentino E, Strocchi E, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vascular Health & Risk Management 2007;3(6):999‐1005. - PMC - PubMed
Yip 2008 {published data only}
    1. Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008;94(5):573‐80. - PubMed

Additional references

Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Available from www.cochrane‐handbook.org.
Heran 2009a
    1. Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD003823.pub2] - DOI - PMC - PubMed
Heran 2009b
    1. Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD003822.pub2] - DOI - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Musini 2010
    1. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD000028.pub2] - DOI - PubMed
Wright 2009
    1. Wright JM, Musini VM. First‐line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources